Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance?

Jul 1, 2017 by in CARDIOLOGY Comments Off on Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance?

© Springer International Publishing Switzerland 2015Maciej Banach (ed.)Combination Therapy In Dyslipidemia10.1007/978-3-319-20433-8_16 16. Drug Evaluation: Olmesartan Medoxomil + Rosuvastatin for the Treatment of Dyslipidemia and Concomitant Risk Factors: A Chance for Better Compliance? Joanna Gozdzikiewicz-Lapinska1 and…

read more

Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

Jul 1, 2017 by in CARDIOLOGY Comments Off on Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

Fig. 15.1 The benefits of fenofibrate/simvastatin combination therapy in different clinical dyslipidemic patterns Although some evidence suggests a possible heightened risk for myopathy and rhabdomyolysis [11], the combination of statin…

read more

The Cardiovascular Polypill in the Prevention of Cardiovascular Disease

Jul 1, 2017 by in CARDIOLOGY Comments Off on The Cardiovascular Polypill in the Prevention of Cardiovascular Disease

© Springer International Publishing Switzerland 2015Maciej Banach (ed.)Combination Therapy In Dyslipidemia10.1007/978-3-319-20433-8_14 14. The Cardiovascular Polypill in the Prevention of Cardiovascular Disease Melvin Lafeber1   (1) Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands…

read more

Statins and Fibrates: Should They Be Recommended?

Jul 1, 2017 by in CARDIOLOGY Comments Off on Statins and Fibrates: Should They Be Recommended?

(1) Department of Hypertension, Medical University of Lodz, Lodz, Poland (2) Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University College London Medical School, University College…

read more

Statins and Niacin: The End of Residual Risk Therapy?

Jul 1, 2017 by in CARDIOLOGY Comments Off on Statins and Niacin: The End of Residual Risk Therapy?

Trial Study population Dose of co-administered drug(s) Duration (median) Primary endpoint Results AIM-HIGH [12] n = 3414 Aged > 45 years, established CVD (documented stable CAD, cerebrovascular or carotid disease, or PAD)…

read more

Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction

Jul 1, 2017 by in CARDIOLOGY Comments Off on Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction

CKD stage Description GFR (ml/min per 1.73 m2) 1 Kidney damage with normal or increased GFR ≥90 2 Kidney damage with mild decreased GFR 60–89 3 Moderate decreased GFR 30–59…

read more

Urgent Surgery Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy with a Vitamin K Antagonist, Aspirin, and Clopidogrel

Jul 1, 2017 by in CARDIOLOGY Comments Off on Urgent Surgery Early After Percutaneous Coronary Intervention in a Patient with Atrial Fibrillation on Triple Therapy with a Vitamin K Antagonist, Aspirin, and Clopidogrel

Fig. 9.1 Coronary angiography of the left coronary artery (AP view cranial) showing high-grade stenosis of the left anterior descending (LAD). AP antero-posterior Table 9.1 CHA2DS2-VASc score and associated risk…

read more
Get Clinical Tree app for offline access